Furthermore, reduced NDRG2 expression was published in high-risk adenoma, colorectal carcinoma [27]–[30], glioblastoma [31] thyroid cancer [32], esophageal cancer [33] renal cancer [34], gallbladder carcinoma [35] and breast cancer [36]. Here, NDRG2 is linked to colorectal carcinoma.